The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


About Nordic NanoVector

Nordic Nanovector is focusing on the development and commercialization of novel targeted therapeutics for haematological cancers. The Company's lead clinical-stage product opportunity is Betalutin, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs) designed to improve upon and complement current options for the treatment of Non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.

Nordic NanoVector Headquarter Location

Kjelsåsveien 168 B

Oslo, NO-0884,


+47 22 18 33 01

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nordic NanoVector

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nordic NanoVector is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Nordic NanoVector Patents

Nordic NanoVector has filed 9 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Monoclonal antibodies
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Tables of nuclides, Immunology, Clusters of differentiation, Monoclonal antibodies for tumors


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Tables of nuclides, Immunology, Clusters of differentiation, Monoclonal antibodies for tumors



Latest Nordic NanoVector News

COMUNICADO: Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin® in 3L R and R Follicular Lymphoma (2)

Jul 5, 2022

Webcast to be held at 08.30 CEST on Wednesday 6 July OSLO, Norway, July 5, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL). Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the Board of Directors (Board) has taken the difficult decision to discontinue the study. No further patients will be enrolled into PARADIGME. The PARADIGME trial enrolled a total of 109 patients. The Company will now ensure a wind-down of PARADIGME in a structured manner ensuring patients receive the best possible care during this period. While Betalutin®, at the selected dose of 15 MBq/kg after a pre-dose of 40 mg lilotomab (40/15), has continued to display an attractive safety profile and positive signs of efficacy in some patients, the Board considers that the observed profile does not fully meet the objectives set out for the PARADIGME study. Only one out of three patients responded to the treatment with the average duration of the response of approximately six months. As a result, the Board is of the opinion that the demonstrated profile is no longer sufficiently competitive to bring Betalutin® to the market in the third line relapsed and refractory FL indication, within a timeframe that makes financial and commercial sense for the Company. The Company still believes there could be a market for Betalutin® in light of its safety profile, promising efficacy in earlier lines of therapy and unique feature of being delivered as a one-time dose. However, a potential new development programme would need to be conducted in a different patient population and line of treatment. The Company will therefore explore potential partnerships and will also seek advice from the US Food and Drug Administration (FDA) to discuss if there could be a possible way forward for Betalutin® in an alternative setting. The Company will now focus its efforts and resources on developing its pipeline of proprietary CD37-targeting products from which Nordic Nanovector believes it can create value for shareholders over the longer term. These pipeline opportunities include: · Humalutin®, a radioimmunotherapy candidate based on a chimeric anti-CD37 antibody and the beta-emitting radionuclide lutetium-177 for non-Hodgkin lymphoma (NHL). · Alpha37, an alpha-emitting radioimmunotherapy candidate based on a chimeric anti-CD37 antibody conjugated to lead-212, currently being explored with partner OranoMed for relapsed/refractory chronic lymphocytic leukaemia. · A portfolio of fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases. · A CD37 DOTA CAR-T cell opportunity in haematological cancers, which is the subject of a research collaboration with the University of Pennsylvania. Following the decision to discontinue PARADIGME, the Board has also decided to implement a restructuring of the Company with immediate effect with the purpose of reducing costs where necessary to enable support of essential activities associated with development of the pipeline. The Company's cash position at the end of Q2 2022 was approximately NOK 280m (end of Q1 NOK 356.3m). Full Q2 results will now be reported on 31 August. Chairman, Jan H. Egberts commented: "The decision to discontinue PARADIGME is extremely disappointing not only for the Nordic Nanovector team, but also for patients, healthcare providers and our shareholders as there continues to be an unmet medical need in frail and elderly patients with Follicular Lymphoma. The new independently reviewed data from PARADIGME, in an increasingly competitive market and with the slow speed of recruitment makes progressing PARADIGME further very difficult. Consequently, the Board no longer sees a viable path to commercialisation in the current indication that would make sense for the Company and its shareholders. We are extremely grateful to all the clinical investigators and patients who have participated in PARADIGME." CEO, Erik Skullerud commented: "Our focus will now shift to our pipeline of other CD37-targeting assets, which give us multiple shots on goal, including Humalutin®, Alpha37, a portfolio of fully humanized anti-CD37 antibodies and the CD37 CAR-T. We look forward to communicating our development plans for these assets in more detail in the coming months." Nordic Nanovector will host a webcast at 08.30 CEST on Wednesday 6 July, elaborating on the strategic decision to stop PARADIGME and including a Q&A session. To join the webcast please sign up via our website . For further information, please contact: IR enquiries

Nordic NanoVector Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nordic NanoVector Rank

  • When was Nordic NanoVector founded?

    Nordic NanoVector was founded in 2009.

  • Where is Nordic NanoVector's headquarters?

    Nordic NanoVector's headquarters is located at Kjelsåsveien 168 B, Oslo.

  • What is Nordic NanoVector's latest funding round?

    Nordic NanoVector's latest funding round is IPO.

  • How much did Nordic NanoVector raise?

    Nordic NanoVector raised a total of $8.33M.

  • Who are the investors of Nordic NanoVector?

    Investors of Nordic NanoVector include HealthCap Venture Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.